Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ:ABOS
Want to see ABOS full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.35Last Year’s EPS
-0.68Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone driven by on-track clinical execution (ALTITUDE-AD), imminent milestones (ALTITUDE top-line readout late 2026; licensing decision for two EBD candidates in Q2 2026), encouraging preclinical EBD data (≈14–40x brain exposure), and controlled operating expenses. Key risks tempering the outlook include a cash runway only into early 2027 (necessitating future financing if programs extend), pending binary Phase II results that will determine the program's trajectory, competition and skepticism around the amyloid class, and the EBD program still being preclinical with an IND targeted for mid-2027.Company Guidance
ALTITUDE-AD Phase II On Track with Top-Line Readout Expected Late 2026
ALTITUDE-AD execution remains on track; participants transitioning into the 12-month open-label extension with a high conversion rate. The study is well-powered (≈542 subjects) to detect a statistically significant difference after 18 months on the primary endpoint (iADRS) and will report key secondary endpoints (CDR-SB), ARIA rates and biomarkers.
Dose Strategy and Target Engagement
ALTITUDE-AD is evaluating two active doses (35 mg/kg and 50 mg/kg) that bracket the exposure range shown to achieve pharmacodynamic target engagement in INTERCEPT-AD Phase I, enabling assessment of dose-related efficacy and safety.
Enhanced Brain Delivery (EBD) Program Progress & Imminent Candidate Licenses
EBD preclinical work is positive; company intends to exercise option to license two JCR Pharma-developed compounds in Q2 2026 and expects an IND filing targeted for mid-2027. EBD aims to enable improved brain penetration, broader distribution and patient-friendly subcutaneous dosing.
Substantial Brain Exposure Improvements in Preclinical Studies
In preclinical primate studies, EBD candidates demonstrated approximately 14–40x higher brain exposure vs. non-carrier constructs, with improved distribution across multiple brain regions — a key rationale for pursuing oligomer-targeted cargo via carrier technology.
Strong KOL and Physician Interest
KOL feedback and clinician interactions show significant interest and anticipation for sabirnetug due to its oligomer-targeted mechanism and potential for differentiation from approved anti-amyloid agents.
Operational Screening Efficiency Improvement with Plasma Biomarker
Using plasma p-tau217 as a screening step reduced negative amyloid PET scans from ~60% to under 20%, improving screening efficiency by more than two-thirds and shortening enrollment time (completed enrollment in ~10 months).
Balance Sheet Strengthened by Private Placement
Cash and marketable securities totaled $128.4 million as of March 31, 2026. A private placement in March grossed $35.75 million to support the EBD program and increased the quarter-over-quarter cash balance.
Controlled Operating Spend Leading to Lower Opex in Q1
Q1 2026 R&D expenses were $16.5 million (lower YoY driven by reduced manufacturing/material and CRO costs) and G&A was $4.7 million (lower legal, accounting, consulting, insurance), demonstrating operational cost control while advancing programs.
ABOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $2.57 | $2.48 | -3.50% |
Mar 26, 2026 | $2.63 | $2.55 | -3.04% |
Nov 12, 2025 | $1.97 | $1.95 | -1.02% |
Aug 12, 2025 | $1.42 | $1.26 | -11.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Acumen Pharmaceuticals, Inc. (ABOS) report earnings?
Acumen Pharmaceuticals, Inc. (ABOS) is schdueled to report earning on Aug 17, 2026, After Close (Confirmed).
What is Acumen Pharmaceuticals, Inc. (ABOS) earnings time?
Acumen Pharmaceuticals, Inc. (ABOS) earnings time is at Aug 17, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABOS EPS forecast?
ABOS EPS forecast for the fiscal quarter 2026 (Q2) is -0.35.